Shlomit Halachmi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shlomit Halachmi has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Aftin Ross
US Food and Drug Administration, Silver Spring, Maryland
1 shared publicationClarence Murray
US Food and Drug Administration, Silver Spring, Maryland
1 shared publicationDan Ben-Amitai
Pediatric Dermatology Unit, Schneider Children’s Medical Center, Petach Tikva, Israel
1 shared publication- Ester Segal
Technion – Israel Institute of Technology
1 shared publication H. Leonard
1 shared publication- Hadar Israeli
Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel
1 shared publication
Latest Publications
- 17 August 2021
- Published by American Medical Association (AMA) in JAMA
- Vol. 326 (7) , 676-677
A Systematic Review of Filtering Facepiece Respirator Reprocessing
To the Editor Dr Schumm and colleagues recently provided a detailed review of decontamination methods for disposable filtering facepiece respirators (FFRs).1 We wish to update readers of JAMA on the most recent US Food and Drug Administration (FDA) recommendations about use of decontaminated FFRs.2 Disposable FFRs are intended for single use. In March 2020, the Centers for Disease Control and Prevention (CDC) provided guidance on limited reuse of FFRs in health care settings as part of crisis capacity conservation strategies.3 The FDA believes there is now an adequate supply of respirators for health care personnel and facilities to transition away from decontamination or bioburden reduction of disposable respirators for reuse. Specific FDA recommendations include (1) limit decontamination of disposable respirators; (2) reserve respirator reuse for when supplies are insufficient; and (3) if reusable respirators are needed, elastomeric respirators and powered air-purifying respirators (PAPRs), which are designed to be reusable, are preferred.
- 17 August 2021
- Published by American Medical Association (AMA) in JAMA
- Vol. 326 (7) , 676-677
A Systematic Review of Filtering Facepiece Respirator Reprocessing
To the Editor Dr Schumm and colleagues recently provided a detailed review of decontamination methods for disposable filtering facepiece respirators (FFRs).1 We wish to update readers of JAMA on the most recent US Food and Drug Administration (FDA) recommendations about use of decontaminated FFRs.2 Disposable FFRs are intended for single use. In March 2020, the Centers for Disease Control and Prevention (CDC) provided guidance on limited reuse of FFRs in health care settings as part of crisis capacity conservation strategies.3 The FDA believes there is now an adequate supply of respirators for health care personnel and facilities to transition away from decontamination or bioburden reduction of disposable respirators for reuse. Specific FDA recommendations include (1) limit decontamination of disposable respirators; (2) reserve respirator reuse for when supplies are insufficient; and (3) if reusable respirators are needed, elastomeric respirators and powered air-purifying respirators (PAPRs), which are designed to be reusable, are preferred.
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S192
Urinary tract infection diagnosis and antimicrobial susceptibility testing within <90 minutes
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S192
Urinary tract infection diagnosis and antimicrobial susceptibility testing within <90 minutes
- 17 May 2013
- Published by Springer Nature in Lasers in Medical Science
- Vol. 29 (1) , 321-324
Treatment of the skin manifestations of hereditary hemorrhagic telangiectasia with pulsed dye laser
Hereditary hemorrhagic telangiectasia (HHT) is a familial disorder, in which variably sized arteriovenous malformations develop in the skin, respiratory tract, central nervous system, and gastrointestinal and urogenital tracts. Bleeding is a major problem in the abnormal vessels, primarily in the nose and internal lesions. Skin lesions, in contrast, do not generally bleed spontaneously but pose a significant cosmetic concern. The lesions are characteristically small caliber vessels located in the dermis. As such, they are ideal targets for vascular lesions. Eight patients with cutaneous facial lesions of HHT were treated by pulsed dye laser. All patients exhibited excellent (75–100 %) clearance after a mean of 2.6 treatments (range 1–8). In comparison, a control group of patients with non-HHT facial telangiectasia required a mean of 1.9 (range 1–5; p < 0.05) treatments. No adverse events were reported in either group. The study confirms the safety and efficacy of PDL in the management of the cutaneous lesions of HHT.
- 17 May 2013
- Published by Springer Nature in Lasers in Medical Science
- Vol. 29 (1) , 321-324
Treatment of the skin manifestations of hereditary hemorrhagic telangiectasia with pulsed dye laser
Hereditary hemorrhagic telangiectasia (HHT) is a familial disorder, in which variably sized arteriovenous malformations develop in the skin, respiratory tract, central nervous system, and gastrointestinal and urogenital tracts. Bleeding is a major problem in the abnormal vessels, primarily in the nose and internal lesions. Skin lesions, in contrast, do not generally bleed spontaneously but pose a significant cosmetic concern. The lesions are characteristically small caliber vessels located in the dermis. As such, they are ideal targets for vascular lesions. Eight patients with cutaneous facial lesions of HHT were treated by pulsed dye laser. All patients exhibited excellent (75–100 %) clearance after a mean of 2.6 treatments (range 1–8). In comparison, a control group of patients with non-HHT facial telangiectasia required a mean of 1.9 (range 1–5; p < 0.05) treatments. No adverse events were reported in either group. The study confirms the safety and efficacy of PDL in the management of the cutaneous lesions of HHT.